When Mercedes was informed by her physician that she could possibly be prescribed GLP-1 weight reduction jabs in 2024, she broke down. “[When] she stated sure, I cried in her workplace. And I didn’t actually cease crying for every week,” she stated.
“Lastly, after being obese my whole life, this was going to avoid wasting me. My battle, my burden, my disgrace was lastly going to come back to an finish.”
However as time went on it was hope, not weight, that fell away.
“I used to be on [Ozempic] for 9 months. After which I went on Wegovy for 4 months, then Contrave [an oral, non-GLP-1 medication], after which Mounjaro, and that was for a number of months, after which 9 months in the past I began on Zepbound,” stated Mercedes. “Nothing has labored.”
A lately retired instructor in her 50s, Mercedes is amongst a small proportion of individuals for whom the highly effective new weight-loss medicine, championed by celebrities for his or her transformative results, don’t work.
Ozempic, a kind 2 diabetes medicine, and Wegovy, which is licensed for weight reduction, each include a drug known as semaglutide that mimics a hormone that happens naturally in our our bodies: GLP-1. These drugs cut back the speed at which meals is emptied from the abdomen, suppresses urge for food and improve the manufacturing of insulin – that means many individuals shed pounds.
Mounjaro and Zepbound, additionally now family names, have a fair higher weight-loss impact. They each include the drug tirzepatide which mimics each GLP-1 and one other hormone.
The joy round such “GLP-1s” has been onerous to overlook: the drugs have grabbed headlines, with medical trials suggesting they will help individuals lose a mean of 15% to twenty% of their physique weight. Studies suggest they could help with situations starting from heart problems and addictions to fatty liver disease. In some instances specialists say the consequences may not be entirely related to weight loss.
However not everybody experiences the advantages. Between 9% and a 3rd of individuals in medical trials lose lower than 5% of their physique weight – relying on the kind of drug and dose used.
Now researchers are attempting to work out why – one thing they are saying may assist medical doctors tailor the usage of the medicine, maximise cost-effectiveness and cut back side-effects.
For Mercedes, the affect of non-response has been profound.
“Except for the truth that it’s not working and that it’s so costly, to say it’s onerous on the conceit is a humongous understatement,” stated Mercedes, who lives in Canada. “It’s been an actual battle, with disgrace and remorse and large payments and disappointment that my very own physique is just not working the best way it ought to.”
Prof Alexander Miras, an weight problems professional at Ulster College, stated the efficacy of the medicine couldn’t be blamed on sufferers. “If the drug doesn’t cut back starvation and meals consumption for somebody, it’s simply not going to work,” he stated.
Mercedes stated she has tried onerous to stay to way of life modifications alongside the drugs however, for her, the jabs didn’t suppress fixed, intrusive ideas about meals.
“I simply thought: ‘No, I’ve obtained to get someplace … I’m going to die of weight problems’,” she stated. “I used to be actually strict with myself for a month – however the cravings, which I can solely name like heroin withdrawal … it’s simply overwhelming. And the meals speak by no means ended.”
The intense effort paid off, to an extent. “I can actually say I misplaced 20 kilos in that month, however not due to the medicine,” she stated.
Mercedes is definitely not alone: the Guardian has heard from dozens of individuals for whom GLP-1 drugs have had little impact.
Yury Okay, 57, additionally from Canada, stated he tried plenty of weight reduction programmes earlier than beginning Wegovy for weight problems. He workouts about 5 days every week, primarily with kettlebells, and doesn’t eat junk meals or quick meals.
Whereas Yury stated he noticed some enhancements in his blood sugar ranges and ldl cholesterol whereas utilizing the medicine, in addition to a discount in meals noise and urge for food, he discovered his weight barely modified.
“I began Wegovy at about 242lb and, after six months, I used to be nonetheless about 242lb. My weight can fluctuate somewhat due to water, however primarily there was no significant weight reduction,” he stated. He additionally skilled disagreeable unintended effects, together with constipation and delicate pores and skin.
“There’s a lot dialogue about GLP-1 drugs as in the event that they work for everybody, and that was not my expertise. While you put within the effort with weight loss program and train, take the medicine precisely as prescribed, and nonetheless see little profit, it’s troublesome to not really feel upset,” he stated.
Lucille*, 53, who relies in Luxembourg, informed the Guardian she has been taking GLP-1 drugs for 4 years – initially to assist with insulin resistance – beginning on a each day injection of a GLP-1 medicine known as Saxenda, earlier than switching to Ozempic.
But regardless of being efficient at first, Lucille says the drugs not assist her shed pounds – even after switching to Mounjaro and taking the very best dose. “It’s as if nothing is having an impact any extra,” she says. “The Mounjaro 5mg [dose] is outrageously costly and thus far none of those drugs have been accepted by my medical insurance,” she provides.
At current, the rationale for such variations in response stays unclear. “The brief reply to why some folks don’t reply is we don’t actually know,” stated Miras.
He stated analysis had advised components resembling motivation, intelligence, training and socioeconomics didn’t predict how sufferers would reply to GLP-1 drugs.
However different traits may do. “We all know, for instance, that age performs a task – so older folks lose much less weight. Intercourse performs a task – males lose lower than ladies,” stated Miras. “[And] folks with sort 2 diabetes lose much less weight in comparison with folks with out.”
Research have additionally advised ancestry may have an effect, with the drugs handiest in folks of European ancestry, and least efficient in folks of African American ancestry.
Dr Mahesh Umapathysivam, an endocrinologist and medical researcher at Adelaide College in Australia, stated it was believable that hormones may have an impact too.
“There’s rising proof that oestrogen alters GLP-1 response. We see that with the distinction between male response and feminine response. Additionally, we all know from a few of the physiological research that point of menstrual cycle additionally alters GLP-1 response,” he stated.
“Lastly, the usage of menopausal hormone alternative remedy – which accommodates oestrogen – is related to higher weight reduction in semaglutide customers.”
Then there may be the matter of genetics. A recent study highlighted the potential position of a genetic variant that impacts receptors within the mind upon which the medicine work.
“Individuals carrying the genetic variant, we discovered lose about an additional 0.76kg (1.6 lbs) on common, and individuals who carry two copies of the variant double that,” stated Adam Auton, vice-president of human genetics on the 23andMe Analysis Institute, and the senior creator of the research.
“For folks with two copies, this accounts for about 10% of the burden folks may count on to lose on these drugs.”
Umapathysivam and colleagues have recently published a study into two genetic variants that have an effect on the manufacturing of an enzyme, often called PAM, that modifies many hormones together with GLP-1. The crew discovered folks with such variants seem to indicate resistance to GLP-1.
“GLP-1 resistance merely means a given quantity of GLP-1 has much less impact on the physique,” Umapathysivam stated. “The implication for therapy is {that a} sure dose of GLP-1 in somebody with resistance may imply much less weight reduction, much less glucose decreasing, much less insulin secretion or much less slowing to the gastric emptying.”
Regardless of rising analysis, it’s not but doable to precisely predict who will reply to weight reduction jabs and who received’t.
However there are causes for folks like Mercedes to be hopeful. A collection of promising new medicine are in growth. “Another choice is to alter sufferers to a non-GLP-1 based mostly drug known as Mysimba [the UK brand name for Contrave]. It really works in the identical elements of the mind, however simply barely in another way and subsequently could also be price attempting,” stated Miras. “It’s not out there within the NHS, simply privately.”
For some who battle to shed pounds with GLP-1 drugs, weight-loss surgical procedure stands out as the solely choice left. And, Miras says, “[A] lack of response to GLP-1 based mostly medicine doesn’t predict lack of response to [bariatric] surgical procedure.”
And for individuals who lose little to no weight on GLP-1 drugs, the message is evident. “It’s not your fault and it’s not the drug’s fault both, that is purely luck,” stated Miras. “I’ve seen it earlier than, it’s not quite common, but it surely does occur.”
Mercedes started GLP-1 drugs with enormous quantities of hope and expectation. “There was simply a lot publicity round it. So many individuals [using the drugs said]: ‘Oh, I forgot to eat lunch,’ that I suppose subconsciously I simply form of ignored the prospect that … the medicine didn’t work,” she stated.
“I want I knew if there have been different folks on the market, like me, for whom [GLP-1s] are simply not efficient in any respect.”
*Some names have been modified
